The global pharmaceutical industry experienced a 7% rise in the number of immuno-oncology-related patent applications in Q2 2023 compared with the previous quarter. The total number of immuno-oncology-related grants rose by 17% in Q2 2023, according to GlobalData’s Patent Analytics. A detailed classification of therapy and technologies, regulatory and market access details and pipeline analysis for immuno-oncology are included in GlobalData’s Immuno-Oncology – Thematic Research report. Buy the report here.
Notably, the number of immuno-oncology-related patent applications in the pharmaceutical industry was 182 in Q2 2023, versus 170 in the prior quarter.
The top five companies accounted for 13% of patenting activity
Analysis of patenting activity by companies shows that Immatics filed the most immuno-oncology patents within the pharmaceutical industry in Q2 2023. The company filed 7 immuno-oncology-related patents in the quarter, compared with 30 in the previous quarter. It was followed by Fred Hutchinson Cancer Research Center with 6 immuno-oncology patent filings, Bristol-Myers Squibb (4 filings), and Technion Israel Institute of Technology (3 filings) in Q2 2023.
Patenting activity was driven by the US with a 49% share of total patent filings
The largest share of immuno-oncology related patent filings in the pharmaceutical industry in Q2 2023 was in the US with 49%, followed by China (7%) and Japan (5%). The share represented by the US was 18% higher than the 32% share it accounted for in Q1 2023.
For further understanding of GlobalData's Immuno-Oncology – Thematic Research buy the report here.